US filing accepted for inhaled treprostinil for PAH
This article was originally published in Scrip
Executive Summary
United Therapeutics' NDA for its lead developmental product, an inhaled formulation of treprostinil for pulmonary arterial hypertension (PAH), has been accepted by the US FDA.